{"id":28860,"date":"2016-11-21T13:26:57","date_gmt":"2016-11-21T12:26:57","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=28860"},"modified":"2016-11-24T13:35:09","modified_gmt":"2016-11-24T12:35:09","slug":"novartis-compera-selexys","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/novartis-compera-selexys\/","title":{"rendered":"Novartis buys Selexys"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.rsi.ch\/news\/economia\/Selexys-Pharmaceutical-ha-sede-a-Oklahoma-City-8344273.html\/ALTERNATES\/LANDSCAPE_744\/Selexys%20Pharmaceutical%20ha%20sede%20a%20Oklahoma%20City\" alt=\"Risultati immagini per Selexys Pharmaceutical\" width=\"312\" height=\"175\" \/>Novartis is ramping up its hematology research activities. The pharmaceutical company acquired the US Selexys Pharmaceutical.<\/p>\n<p>The purchase price could reach 665 million dollars (671 million francs). This acquisition comes after the results obtained in phase 2 of the clinical trial with the compound SelG1, an experimental treatment to treat and soothe the pain crises of patients with sickle cell anemia, also called sickle cell anemia.<\/p>\n<p>In 2013, about 3.2 million people had sickle cell disease, while another 43 million had sickle cell trait.<\/p>\n<p><a href=\"http:\/\/www.rsi.ch\/news\/economia\/Novartis-compera-Selexys-8344846.html\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Monday 21\/11\/16 \u2013 RSI.ch<\/span><\/a><\/p>\n<p>Related news: <a href=\"http:\/\/www.elglobal.net\/industria-farmaceutica\/kymos-pharma-compra-pharmaprogress-HB614009\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Kymos Pharma buys Pharmaprogress<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Novartis sta incrementando le sue attivit\u00e0 nel campo della ricerca ematologica. La societ\u00e0 farmaceutica ha fatto sua la statunitense Selexys Pharmaceutical. Il prezzo di acquisto potrebbe raggiungere i 665 milioni di dollari (671 milioni di franchi). Questa acquisizione giunge dopo i risultati ottenuti nella fase 2 della sperimentazione clinica con il composto SelG1, trattamento sperimentale &hellip;<\/p>","protected":false},"author":4,"featured_media":2948,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-28860","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=28860"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28860\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/2948"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=28860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=28860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=28860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}